Related Experiment Video
Updated: Aug 13, 2026

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
Published on: December 14, 2020
[Oral cavity manifestations of gastroesophageal reflux disease]
Abstract:
The aim of the study was to investigate changes in the oral cavity and the gastroesophageal zone of the patients receiving rabeprazol, a proton pump inhibitor (PPI). The subjects were 88 patients with gastroesophageal reflux disease (GERD), who had changes in the oral cavity typical of this disease. The patients were divided into four groups. Group I included patients with non-erosive reflux disease; the other three groups were formed according to the degree of the severity of reflux esophagitis in accordance with Los Angeles classification of GERD: A, B, and C. The patients were administered rabeprazol as a PPI. The study found that oral cavity changes are associated with the degree of the gastroesophageal reflux. The study demonstrated high efficacy of rabeprazol in GERD patients with oral cavity changes.
Related Concept Videos
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Gastroesophageal Reflux Disease
Gastroesophageal Reflux Disease I: Meaning and Pathophysiology
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Other Disorders of Digestive System

